Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Immuneering (IMRX) Other Operating Expenses (2022 - 2024)

Immuneering has reported Other Operating Expenses over the past 3 years, most recently at $7317.0 for Q4 2024.

  • Quarterly results put Other Operating Expenses at $7317.0 for Q4 2024, changed 0.0% from a year ago — trailing twelve months through Dec 2024 was $29268.0 (changed 0.0% YoY), and the annual figure for FY2025 was $29267.0, changed 0.0%.
  • Other Operating Expenses for Q4 2024 was $7317.0 at Immuneering, roughly flat from $7317.0 in the prior quarter.
  • Over the last five years, Other Operating Expenses for IMRX hit a ceiling of $8103.0 in Q1 2022 and a floor of $7316.0 in Q4 2022.
  • Median Other Operating Expenses over the past 3 years was $7317.0 (2022), compared with a mean of $7382.4.
  • Peak annual rise in Other Operating Expenses hit 0.01% in 2023, while the deepest fall reached 9.7% in 2023.
  • Immuneering's Other Operating Expenses stood at $7316.0 in 2022, then increased by 0.01% to $7317.0 in 2023, then changed by 0.0% to $7317.0 in 2024.
  • The last three reported values for Other Operating Expenses were $7317.0 (Q4 2024), $7317.0 (Q3 2024), and $7317.0 (Q2 2024) per Business Quant data.